Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tamara Ghanem

- PMLiVE

Getting in-sync with Public Health at SYNC 2024

Medscape Education is bringing its public health efforts to Washington, DC for the SYNC conference on HIV, HCV, STIs, Harm Reduction, and LGBTQ health. During the conference, Lindsey will present...

Medscape Education Global

- PMLiVE

Disconnected pharma: Navigating digital challenges and priorities in 2024

We are delighted to present Graphite’s research whitepaper for 2024 — and this year we are able to share the challenges and priorities that digital leaders are finding, in this...

Graphite Digital

- PMLiVE

Health literacy – levelling the playing field

In health, there is freedom. - Henri Frederic Amiel. Our health can powerfully shift the course of our lives. And so it follows that autonomy over our health should be...

Wallace Health

EU flag

EC approves Celltrion’s omalizumab biosimilar Omlyclo for immunological conditions

The drug can be used to treat patients with conditions including chronic spontaneous urticaria

- PMLiVE

Novartis shares positive late-stage results for Fabhalta in rare kidney disease C3 glomerulopathy

Approximately one to two people per million worldwide are diagnosed with C3G every year

- PMLiVE

Study reveals inflammation caused by infections could contribute to MS progression

The progressive, neurodegenerative disease is estimated to affect more than 130,000 people in the UK

- PMLiVE

Patient-centricity – keeping patients’ views and experiences front and centre

By Joella Melville

- PMLiVE

Strategic planning – enabling organisations to move forward successfully

By Dominic Elliston

- PMLiVE

The evolution of hype

Beware the shock jocks of management ideas

- PMLiVE

Takeda and Degron enter molecular glue degrader partnership worth over $1.2bn

The companies will focus on targets in oncology, neuroscience and inflammation

- PMLiVE

Agenda announced for FlyPharma Vienna 2024

The conference will take place on 23 to 24 October at Vienna AirportCity

- PMLiVE

Merck KGaA signs definitive agreement to acquire Mirus Bio in deal worth $600m

The deal aims to advance Merck’s viral vector manufacturing of cell and gene therapies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links